Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab in Combination With Chemotherapy in HER2-positive Breast Cancer
NCT07102381Phase 2Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of zanidatamab in HER2-positive breast cancer (3 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Pathologic Complete Response at 8 months. Started Sep 2025; status: recruiting.
02
Drugs
zanidatamab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07102381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07102381.